A RANDOMIZED TRIAL OF 2 CISPLATIN-CONTAINING CHEMOTHERAPY REGIMENS IN PATIENTS WITH STAGE-III-B AND STAGE-IV NONSMALL CELL LUNG-CANCER

ERKISI M., DORAN F., BURGUT R., KOCABAS A.

LUNG CANCER, vol.12, no.3, pp.237-246, 1995 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 12 Issue: 3
  • Publication Date: 1995
  • Doi Number: 10.1016/0169-5002(95)00447-9
  • Journal Name: LUNG CANCER
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.237-246
  • Çukurova University Affiliated: No

Abstract

Seventy-four newly diagnosed patients with histologically proven Stage III-B and IV non-small cell lung cancer were randomized to receive either cisplatin: 20 mg/m(2) x day x 5, ifosfamide: 1.8 g/m(2) x day x 5, mesna: 1.2 g/m(2) x day x 5, etoposide: 100 mg/m(2) x day x 5 (ICE) or cisplatin: 20 g/m(2) x day x 5 and etoposide: 100 mg/m(2) x day x 5. Response rates were 59% in the ICE and 40% in the CE arm with a significant advantage in response duration and overall survival in the ICE receiving patients (P = 0.03, P = 0.0008). As we used granulocyte colony stimulating factor (G-CSF) very frequently, myelotoxicity remained substantial but acceptable.